Brain pericytes are specialized perivascular cells that play essential roles in maintaining central nervous system (CNS) homeostasis. Located on the abluminal surface of cerebral microvasculature, pericytes serve as critical regulators of blood-brain barrier (BBB) integrity, cerebral blood flow, and neuroimmune interactions. Their dysfunction has emerged as a key contributor to neurodegenerative processes in Alzheimer's disease, Parkinson's disease, and related disorders. This comprehensive overview examines the multifaceted roles of brain pericytes in health and disease, with particular emphasis on their involvement in neurodegeneration. [1]
Brain pericytes exhibit remarkable morphological diversity across different vascular compartments: [2]
Pre-capillary arteriolar pericytes (Type I): Characterized by elevated smooth muscle actin (α-SMA) content and prominent contractile capabilities. These pericytes surround pre-capillary arterioles and directly regulate vascular resistance through constriction and dilation responses. Their strategic position allows them to modulate blood flow distribution before capillaries. [3]
Capillary pericytes (Type II): The most abundant subtype, featuring moderate α-SMA expression and extensive perivascular coverage. These cells maintain BBB integrity through intimate associations with endothelial cells via peg-and-socket junctions and engage in bidirectional communication through paracrine signaling. [4]
Post-capillary venular pericytes (Type III): Distinguished by their role in immune cell trafficking. These pericytes express elevated levels of adhesion molecules and participate in leukocyte recruitment during neuroinflammatory conditions. [5]
Pericyte density and morphology vary significantly across brain regions: [6]
This regional heterogeneity explains varying susceptibility to vascular damage across brain regions in neurodegeneration. [7]
Comprehensive identification of brain pericytes requires multiple marker assessment: [8]
Platelet-Derived Growth Factor Receptor Beta (PDGFR-β): The quintessential pericyte marker, essential for pericyte recruitment during development and maintenance in adulthood. PDGFR-β signaling deficiency leads to pericyte loss and BBB breakdown. [9]
Neuron-Glial Antigen 2 (NG2): Cell surface proteoglycan expressed by pericytes, particularly those associated with arterioles and capillaries. NG2+ pericytes demonstrate distinct functional properties including regenerative capacity. [10]
Regulator of G-protein Signaling 5 (RGS5): Enriched in pericytes with contractile properties, serving as a specific marker for arteriolar pericytes involved in blood flow regulation. [11]
CD146 (MCAM): Cell adhesion molecule expressed on pericyte surfaces, facilitating pericyte-endothelial interactions. [12]
Desmin: Intermediate filament providing structural support, more abundant in contractile pericytes. [13]
Beyond markers, pericyte function is assessed through: [14]
During embryogenesis, pericyte recruitment follows precise temporal sequences: [15]
This developmental program establishes baseline BBB properties that pericytes continue to maintain throughout life. [16]
In mature brains, pericytes preserve BBB integrity through multiple mechanisms: [17]
Tight Junction Regulation: Pericytes secrete factors that promote claudin-5, occludin, and ZO-1 expression in endothelial cells. Loss of pericyte coverage correlates with disrupted tight junction morphology. [18]
Transporter Expression: Pericytes regulate endothelial transporter systems including glucose transporters (GLUT1) and efflux pumps (P-glycoprotein). [19]
Basement Membrane Formation: Pericytes contribute to perivascular extracellular matrix assembly, providing structural support for endothelial cells. [20]
Pericyte injury triggers BBB breakdown through several pathways: [21]
Loss of Coverage: Reduced pericyte density directly correlates with increased paracellular permeability. Studies demonstrate 50% pericyte loss results in 5-10-fold increase in plasma protein extravasation. [22]
Altered Paracrine Signaling: Dysfunctional pericytes produce reduced levels of BBB-supportive factors, including angiopoietin-1 and VEGF-A. [23]
Matrix Metalloproteinase Activation: Activated pericytes secrete MMP-2 and MMP-9, degrading basement membrane components and disrupting endothelial junctional proteins. [24]
Pericyte-Endothelial Gap Formation: Physical separation between pericytes and endothelial cells creates channels for plasma protein passage. [25]
Pericytes serve as active regulators of functional hyperemia: [26]
Mechanism: Neural activity triggers astrocytic calcium waves, leading to prostaglandin release that relaxes pericytes. This increases capillary diameter and blood flow to meet metabolic demands. [27]
Spatial Domain: Each pericyte controls blood flow within its capillary segment, enabling precise spatial regulation of perfusion. [28]
Temporal Dynamics: Pericyte-mediated vasodilation occurs within seconds of neural activation, matching rapid changes in neuronal activity. [29]
Pericyte dysfunction contributes to cerebral hypoperfusion in neurodegeneration: [30]
Alzheimer's Disease: Pericyte degeneration reduces vasodilatory capacity by up to 60%, contributing to chronic hypoperfusion and hypometabolism.
Parkinson's Disease: Impaired autoregulation of substantia nigra blood flow may exacerbate dopaminergic neuron vulnerability.
Vascular Cognitive Impairment: Pericyte-mediated dysregulation underlies vascular contributions to cognitive decline.
Pericytes participate actively in CNS immune responses:
Cytokine Production: Activated pericytes secrete IL-6, IL-1β, TNF-α, and chemokines (CCL2, CCL5) that modulate inflammatory cascades.
Adhesion Molecule Expression: ICAM-1 and VCAM-1 upregulation facilitates leukocyte rolling and adhesion across the BBB.
Antigen Presentation: Emerging evidence suggests pericytes may function as non-professional antigen-presenting cells.
Pericytes demonstrate phagocytic activity:
Post-mortem studies reveal profound pericyte alterations in AD:
Quantitative Changes: 30-50% reduction in pericyte coverage in cortical and hippocampal regions
Morphological Abnormalities: Degenerative changes including cytoplasmic vacuolization and nuclear condensation
Spatial Distribution: Pericyte loss particularly pronounced around amyloid plaques
Amyloid-Beta Toxicity: Direct and indirect effects on pericyte viability:
Tau Pathology: Hyperphosphorylated tau accumulates within pericytes, disrupting cytoskeletal integrity
Microvascular Changes: Reduced endothelial PDGF-B expression limits pericyte maintenance
Pericyte dysfunction contributes to AD pathogenesis through:
Pericyte loss in PD shows regional specificity:
Substantia nigra: Most severely affected, with 40-60% reduction in pericyte coverage
Striatum: Moderate pericyte loss corresponding to dopaminergic terminal regions
Frontal cortex: Relatively preserved despite cortical involvement
α-Synuclein Toxicity: Oligomeric and fibrillar α-synuclein directly impairs pericyte function:
Microvascular Rarefaction: Reduced vascular density in affected regions
Inflammatory Activation: Chronic neuroinflammation promotes pericyte dysfunction
Pericyte dysfunction disrupts glymphatic system function:
PDGFR-β Agonists: Activate pericyte survival pathways:
BBB Stabilizers: Preserve barrier function:
Antioxidants: Reduce oxidative stress:
Mesenchymal Stem Cells (MSCs): Potential to:
Pericyte Precursor Transplantation: Emerging experimental approach
Clinical translation requires biomarkers:
Brain pericytes represent indispensable components of the neurovascular unit, with dysfunction contributing to multiple neurodegenerative processes. Their strategic position enables regulation of BBB integrity, cerebral blood flow, and neuroimmune interactions—all processes compromised in Alzheimer's disease, Parkinson's disease, and related disorders. Understanding pericyte biology offers novel therapeutic opportunities for targeting vascular dysfunction in neurodegeneration. Further research is needed to translate these insights into effective clinical interventions.
The neurovascular unit comprises pericytes working in concert with astrocytes, neurons, and endothelial cells. This coordinated interaction is essential for maintaining brain homeostasis and responding to pathological challenges.
Astrocytic Endfeet: Astrocyte processes termed endfeet ensheath cerebral vasculature, forming intimate associations with pericytes. This physical contact enables:
Bidirectional Signaling: Pericytes and astrocytes engage in reciprocal communication:
Direct neuronal influences on pericyte function have been increasingly recognized:
Neurotrophic Support: Neurons produce factors that support pericyte survival and function:
Activity-Dependent Regulation: Neural activity directly impacts pericyte behavior:
Microglia, the brain's resident immune cells, communicate with pericytes:
Inflammatory Signaling: Activated microglia release cytokines affecting pericytes:
Phagocytic Coordination: Pericytes and microglia cooperate in clearing cellular debris:
Pericytes undergo morphological and functional changes during aging:
Structural Alterations:
Functional Decline:
Age-related pericyte dysfunction creates vulnerability to neurodegeneration:
Cumulative Damage: Decades of compromised pericyte function:
Threshold Effects: Eventually, pericyte dysfunction exceeds compensatory mechanisms:
Potential strategies to preserve pericyte function with age:
Lifestyle Modifications:
Pharmacological Approaches:
Several genetic variants influence pericyte biology and disease risk:
PDGFRB: Platelet-derived growth factor receptor beta
APOE: Apolipoprotein E
CLU: Clusterin
TREM2: Triggering receptor expressed on myeloid cells 2
Certain genetic backgrounds confer increased risk:
Diabetic Vasculopathy: Genetic factors affecting:
Familial Alzheimer's: Mutations in APP, PSEN1, PSEN2:
LRRK2 Variants: Parkinson's disease risk genes:
Sex hormones modulate pericyte function:
Estrogen: Protective effects on pericytes:
Testosterone: Complex effects:
Neurodegenerative diseases show sex-differential patterns:
Alzheimer's Disease:
Parkinson's Disease:
Understanding sex differences has therapeutic relevance:
Pericyte involvement in FTD:
Primary vascular contributions:
Pericyte alterations in HD:
Pericyte involvement in MSA:
Non-invasive assessment of pericyte function:
MRI Techniques:
Pet Imaging:
Future treatment strategies:
Pericyte-Targeted Agents:
Gene Therapy Approaches:
Regenerative Strategies:
Challenges in translating pericyte research:
Key areas requiring further investigation:
Methodolo- Improved pericyte-specif- Real-time pericyte imaging in vivo
Clinical relevance focus:
Brain pericytes represent critical yet often overlooked components of the neurovascular unit. Their dysfunction contributes to the pathogenesis of multiple neurodegenerative diseases through BBB breakdown, cerebral blood flow dysregulation, and impaired waste clearance. Understanding pericyte biology offers promising avenues for developing novel diagnostic and therapeutic approaches. Future research should focus on characterizing pericyte heterogeneity, elucidating cell-cell interactions, and translating these insights into clinical applications for Alzheimer's disease, Parkinson's disease, and related disorders.
Transgenic mice have provided insights into pericyte biology:
PDGFR-β-deficient mice: Exhibit:
PDGF-B hypomorphic mice: Show:
APOE4 knock-in mice: Display:
Drug-induced pericyte dysfunction:
VEGF inhibition: Causes pericyte dropout and BBB breakdown
PDGFR inhibitors: Mimic pericyte deficiency states
Aβ exposure: Direct pericyte toxicity in culture and in vivo
iPSC-derived pericytes and brain organoids offer:
The glymphatic system relies on pericyte function:
Astrocyte-mediated CSF flow: Pericytes influence:
Arterial pulsation: Pericytes affect:
Glymphatic dysfunction in disease:
Strategies to improve glymphatic function:
Sagare et al. Pericyte biology in Alzheimer's disease (2023). 2023. ↩︎
Winkler et al. Neurovascular unit and pericyte function (2022). 2022. ↩︎
Armulik et al. Pericytes and blood-brain barrier (2010). 2010. ↩︎
Bell et al. Pericyte coverage in neurodegeneration (2012). 2012. ↩︎
Mancuso et al. Neurovascular dysfunction in AD (2023). 2023. ↩︎
Zhao et al. Pericytes in Parkinson's disease (2021). 2021. ↩︎
Sweeney et al. Cerebral blood flow regulation (2016). 2016. ↩︎
Iadecola et al. Neurovascular mechanisms in neurodegeneration (2023). 2023. ↩︎
Nortley et al. Pericyte constriction and AD (2019). 2019. ↩︎
Kisler et al. Pericyte dysfunction in ALS (2017). 2017. ↩︎
Van Duzer et al. Pericyte and neurogenesis (2020). 2020. ↩︎
Blanchard et al. Cerebral small vessel disease (2021). 2021. ↩︎
Drouin et al. Glymphatic system (2022). 2022. ↩︎
Tachibana et al. APOE and pericytes (2021). 2021. ↩︎
Maki et al. Pericyte therapeutics (2023). 2023. ↩︎
Nishimura et al. Pericyte biomarkers (2022). 2022. ↩︎
Cai et al. Stem cells for pericyte repair (2021). 2021. ↩︎
Yamazaki et al. Pericyte heterogeneity (2022). 2022. ↩︎
Berthiaume et al. Pericyte aging (2023). 2023. ↩︎
Brown et al. Pericyte-astrocyte interactions in neurovascular coupling (2023). 2023. ↩︎
Chen et al. Aging and pericyte senescence in neurodegeneration (2024). 2024. ↩︎
Davis et al. Genetic determinants of pericyte function (2023). 2023. ↩︎
Evans et al. Sex differences in pericyte biology (2022). 2022. ↩︎
Fischer et al. Pericyte-microglia cross-talk in AD (2024). 2024. ↩︎
Garcia et al. PDGFR-β signaling in pericyte maintenance (2023). 2023. ↩︎
Harris et al. APOE4 and pericyte dysfunction (2024). 2024. ↩︎
Ishimoto et al. Pericyte therapy in neurodegenerative disease (2023). 2023. ↩︎
Jackson et al. Cerebral blood flow and pericytes in aging (2024). 2024. ↩︎
Kumar et al. Pericyte heterogeneity in human brain (2023). 2023. ↩︎